[Ip-health] FT: Bayer loses bid to block cheap version of cancer drug in India

Mohga Kamal-Yanni mkamalyanni at Oxfam.org.uk
Fri Dec 12 09:23:32 PST 2014


Well done India. Public health is before commercial interest despite the 
enormous pressure on India (thanks to US, EU and pharmaceutical industry).


Best wishes مع أطيب التحيات
___________________________________
Mohga (Dictating to the computer so please forgive silly mistakes) also 
have computer problems so please forgive delays
Mohga M Kamal-Yanni
Senior health & HIV policy advisor, Oxfam GB
John Smith Drive, Oxford, OX4 2JY, UK (GMT, CET-1, EDT+5, EST+6)
UK Mobile   + 44 (0)777 62 55 884
Follow me @MohgaKamalYanni



From:   Thiru Balasubramaniam <thiru at keionline.org>
To:     "ip-health at lists.keionline.org" <Ip-health at lists.keionline.org>, 
Date:   12/12/2014 16:58
Subject:        [Ip-health] FT: Bayer loses bid to block cheap version of 
cancer  drug in India
Sent by:        "Ip-health" <ip-health-bounces at lists.keionline.org>



http://www.ft.com/intl/cms/s/0/36a2d942-8202-11e4-a9bb-00144feabdc0.html


December 12, 2014 4:01 pm
Bayer loses bid to block cheap version of cancer drug in India

Andrew Ward in London and Amy Kazmin in New Delh

Bayer <http://markets.ft.com/tearsheets/performance.asp?s=de:BAYX> has 
lost
its bid to block a cheap version of the German company’s Nexavar cancer
drug from the Indian market in a landmark ruling that will ensure access 
to
a life-extending medicine. But the decision will also reinforce industry
concerns over threats to intellectual property in the world’s second-most
populous nation.


The Indian Supreme Court rejected Bayer’s appeal against a decision by the
country’s patent controller in 2012
<
http://www.ft.com/cms/s/0/0b00c0cc-0263-11e2-b41f-00144feabdc0.html#axzz3LaOxsVdT
>
to
override the company’s monopoly on Nexavar, which treats kidney and liver
cancers.


The case has been closely watched as a test of India’s willingness to 
challenge
drug patents
<
http://www.ft.com/cms/s/0/2cc8d306-6f3b-11e4-8d86-00144feabdc0.html?siteedition=uk#axzz3LaOxsVdT
>
and
the associated high prices that keep many medicines out of reach of all 
but
the wealthiest members of society.


Bayer has been fighting against the issuing of a compulsory licence that
allowed Natco, an Indian generic drugmaker, to sell Nexavar for just $173 
a
month compared with the $5,500 a month charged by the German company.


On Friday, Bayer said it was “disappointed” by the Supreme Court decision.
“We are analysing the order and will determine any future course of action
afterwards.”


The Lawyers Collective, an Indian human rights group, described it as a
“momentous decision that would have wide-ranging implications for access 
to
medicines”. Médecins Sans Frontières, the medical charity, praised “the
independence of the Indian judiciary” in the face of industry lobbying
<
http://www.ft.com/cms/s/0/bdaf5880-96de-11e3-a274-00144feab7de.html#axzz3LaOxsVdT
>
.


Indian courts have recently rejected patent applications
<
http://www.ft.com/cms/s/0/7e7dbd46-9a95-11e2-b982-00144feabdc0.html#axzz3LaOxsVdT
>
on
drugs from Novartis
<http://markets.ft.com/tearsheets/performance.asp?s=ch:NOVN> and Roche
<http://markets.ft.com/tearsheets/performance.asp?s=ch:ROG>, fuelling
tensions with the industry as well as with western governments. The US has
kept India on a “watchlist” of intellectual property violators.


However, Nexavar is the only case so far in which India has issued a
compulsory licence under rules that allow the government and companies to
seek permission to overturn drug patents in the interests of public 
health.


India’s government in New Delhi had no involvement in the application by
Hyderabad-based Natco to apply for a Nexavar licence nor in the patent
controller’s decision to grant it.


Activists complain that few Indian generics producers are willing to 
pursue
such licences because many have manufacturing, marketing or distribution
tie-ups with the big innovative drug companies.


“There is a huge amount of pressure from multinational companies
discouraging their Indian partners from filing these applications,” said
Leena Menghaney, who works for the MSF campaign on access to affordable
medicines.


Activists had previously appealed to the Indian government to issue
compulsory licences for the breast cancer drug Herceptin, but Roche
subsequently decided to withdraw its patents on the medicine in India. The
drug is now widely available to Indian patients at a fraction of its
previous price.


Nearly 70 per cent of Indian healthcare expenses are paid out of pocket by
patients or their families.


Western drugmakers often accuse India of using public health as a pretext
for boosting the country’s big generic pharmaceuticals industry. They 
worry
that cheap copies of patent-protected medicines will be exported to other
markets and that India’s approach risks undermining global drug 
development.


Shamnad Basheer, an intellectual property rights lawyer, and founder of
SpicyIP, a blog focused on intellectual property rights issues, said big
pharma’s biggest fear was that India would set a precedent for other
emerging economies such as Brazil and South Africa. “They think other
countries will pick up the Indian standard.”
_______________________________________________
Ip-health mailing list
Ip-health at lists.keionline.org
http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org





Oxfam works with others to overcome poverty and suffering.

Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
A registered charity in England and Wales (no 202918) and Scotland (SC 039042)


More information about the Ip-health mailing list